Climb Biotherapeutics, Inc. (CLYM)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
Climb Bio NASDAQ: CLYM outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright's BioConnect Conference, with management emphasizing two biologic drug programs aimed at immune-mediated diseases, including nephrology and hematology indications.
Climb Bio: 'Buy' On Budoprutug Phase 2 Advancement pMN And Expansions Underway
Climb Bio, Inc. maintains a Buy rating, driven by budoprutug's strong phase 1b and long-term data in primary membranous nephropathy [pMN]. CLYM's phase 2 PrisMN trial in pMN, with initial data expected 2H 2026, is a key catalyst; expansion into SLE and ITP offers additional upside. Budoprutug's versatility, including a subcutaneous formulation and broad B-cell depletion, positions CLYM for competitive advantage in autoimmune disorders.
Is Climb Bio, Inc. (CLYM) Stock Outpacing Its Medical Peers This Year?
Here is how Climb Bio, Inc. (CLYM) and Idexx Laboratories (IDXX) have performed compared to their sector so far this year.
